Greater OS Benefit Among Patients with Advanced Cancer Treated with Matched Targeted Therapy Based on Biomarkers Identified by ctDNA Genotyping By Ogkologos - November 11, 2024 828 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SCRUM-Japan GOZILA study Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR Exploratory 4-year Analysis Continues to Support Adding 3 Years of Ribociclib... October 8, 2025 Favourable Response More Likely with Neoadjuvant Dual Immune Checkpoint Inhibitor Than... April 11, 2024 Keanu Reeves Has A Long History Of Supporting Cancer Research January 13, 2022 Favourable Benefit-Risk Profile of Trastuzumab Deruxtecan in Patients with HER2-positive MBC... May 10, 2023 Load more HOT NEWS Stem cell research: meet the scientist growing ‘mini guts’ in her... EMA Adopts a New Pharmaceutical Form of Selumetinib FDA Approves Pafolacianine for Identifying Malignant Ovarian Cancer Lesions Why the voices of people affected by cancer are critical to...
